The First Treatment Specifically Approved for Huntington's Disease Patients is Now Available in the Uni...( NEW YORK Nov. 24 /- Xenazine(R) (tetr...),Health

NEW YORK, Nov. 24 /PRNewswire/ -- Xenazine(R) (tetrabenazine) Tablets, the first and only U.S. Food and Drug Administration (FDA) approved drug for the treatment of chorea associated with Huntington's Disease (HD), is now available in the United States. Patients, caregivers, physicians and family members have been waiting for decades for a single treatment option. The Huntington's Disease Society of America is pleased that for the first time ever people with HD will have an approved option to consider to treat their chorea. Xenazine, which lessons the effects of chorea, will be distributed by Ovation Pharmaceuticals through a network of specialty pharmacies.

"The launch of Xenazine represents a significant milestone for the patients, families and caregivers affected by HD. After years of advocating for the approval of Xenazine, we are so pleased that it is now available here in the U.S. and that Ovation is committed to making this product accessible to as many individuals as possible who are living with this rare and devastating condition," said Barbara Boyle, National Executive Director/CEO, Huntington's Disease Society of America. Ovation has developed comprehensive patient support programs to ensure that as many qualified individuals as possible can receive Xenazine and to mitigate patients having problems accessing the drug due to financial constraints.

    To find out more about Xenazine and if it is the right treatment for you:

    -- Go see your physician
    -- Call 1-888-882-6013
    -- Visit Xenazineusa.com

Huntington's Disease is a devastating hereditary brain disorder with limited effective treatment options. HD slowly diminishes the affected individual's ability to walk, talk and reason. Eventually, the person with HD becomes totally dependent upon others for his or her care. Huntington's Disease profoundly affects the lives of entire families -- emotionally, socially and ec
'/>"/>